UBS analyst Danielle Antalffy lowered the firm’s price target on Baxter (BAX) to $21 from $24 and keeps a Neutral rating on the shares. Baxter delivered a Q3 sales miss vs. consensus across all businesses excluding Advanced Surgery and also cut its quarterly dividend, the analyst tells investors in a research note. Consensus numbers for 2026 will likely have to come down, and sales growth in 2026 might be tough to come by, the firm says.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAX: